[HTML][HTML] Medical management and prevention of motor complications in Parkinson's disease
Levodopa is the most effective medication for the treatment of the motor symptoms of
Parkinson's disease. However, over time, the clinical response to levodopa becomes …
Parkinson's disease. However, over time, the clinical response to levodopa becomes …
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
MA Cenci, K Skovgård, P Odin - Neuropharmacology, 2022 - Elsevier
Dopamine replacement therapy with l-DOPA is the most efficacious symptomatic treatment
for Parkinson's disease, but its utility is limited by a development of motor fluctuations and …
for Parkinson's disease, but its utility is limited by a development of motor fluctuations and …
[HTML][HTML] D2 dopamine receptors and the striatopallidal pathway modulate L-DOPA-induced dyskinesia in the mouse
Abstract L-DOPA-induced dyskinesia (LID) remains a major complication of Parkinson's
disease management for which better therapies are necessary. The contribution of the …
disease management for which better therapies are necessary. The contribution of the …
Improving the delivery of levodopa in Parkinson's disease: A review of approved and emerging therapies
Levodopa is the most effective drug for the treatment of Parkinson's disease, but its use as
an oral medication is complicated by its erratic absorption, extensive metabolism and short …
an oral medication is complicated by its erratic absorption, extensive metabolism and short …
Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa‐Induced Dyskinesia
E Espa, L Song, K Skovgård, S Fanni… - Movement …, 2023 - Wiley Online Library
Background Current models of levodopa (l‐dopa)‐induced dyskinesia (LID) are obtained by
treating dopamine‐depleted animals with l‐dopa. However, patients with LID receive …
treating dopamine‐depleted animals with l‐dopa. However, patients with LID receive …
[HTML][HTML] Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism
Abstract L-DOPA-induced dyskinesia (LID) is a significant complication of dopamine
replacement therapy in Parkinson's disease (PD), and the specific role of different dopamine …
replacement therapy in Parkinson's disease (PD), and the specific role of different dopamine …
Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model
M dos Santos Pereira, GC Nascimento… - Frontiers in …, 2022 - frontiersin.org
The pharmacological manipulation of neuroinflammation appears to be a promising strategy
to alleviate l-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD). Doxycycline …
to alleviate l-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD). Doxycycline …
Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
Background: Clinical trials for antiparkinsonian drugs aimed at managing motor
complications typically use patient diaries to divide levodopa-induced dyskinesias (LID) into …
complications typically use patient diaries to divide levodopa-induced dyskinesias (LID) into …
[HTML][HTML] Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration
S Grigoriou, E Espa, P Odin, J Timpka… - …, 2023 - Elsevier
Many patients with Parkinson's disease (PD) experiencing l-DOPA-induced dyskinesia (LID)
receive adjunct treatment with dopamine agonists, whose functional impact on LID is …
receive adjunct treatment with dopamine agonists, whose functional impact on LID is …
Doxycycline and its derivative, COL‐3, decrease dyskinesia induced by l‐DOPA in hemiparkinsonian rats
M Bortolanza, GC do Nascimento… - British Journal of …, 2021 - Wiley Online Library
Background and Purpose l‐DOPA‐induced dyskinesia is a debilitating effect of treating
Parkinson's disease with this drug. New therapeutic approaches that prevent or attenuate …
Parkinson's disease with this drug. New therapeutic approaches that prevent or attenuate …